| Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. |
15082792 |
Mol Cell Biol |
| Analysis of methylation-sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer. |
15735726 |
Oncogene |
| Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction. |
21254049 |
Cancer |
| Do serum biomarkers really measure breast cancer? |
19476629 |
BMC Cancer |
| Estrogen receptor alpha (ESR1) mutant A908G is not a common feature in benign and malignant proliferations of the breast. |
15034868 |
Genes Chromosomes Cancer |
| Evaluation of expression based markers for the detection of breast cancer cells. |
16319979 |
Breast Cancer Res Treat |
| Expression signatures of TP53 mutations in serous ovarian cancers. |
20504346 |
BMC Cancer |
| Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. |
16603642 |
Mol Cancer Res |
| Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia. |
21852960 |
PLoS Genet |
| High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer. |
16432260 |
Nucleic Acids Res |
| Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy. |
19208741 |
Mol Cancer Res |
| Isogenic normal basal and luminal mammary epithelial isolated by a novel method show a differential response to ionizing radiation. |
17409405 |
Cancer Res |
| Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients. |
20473856 |
Int J Cancer |
| Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. |
19318476 |
Clin Cancer Res |
| Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. |
19224362 |
Breast Cancer Res Treat |
| Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. |
15897565 |
Clin Cancer Res |
| Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased. |
21586622 |
Cancer Epidemiol Biomarkers Prev |
| Pooling of case specimens to create standard serum sets for screening cancer biomarkers. |
17301268 |
Cancer Epidemiol Biomarkers Prev |
| Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. |
15598772 |
Cancer Epidemiol Biomarkers Prev |
| Role of eotaxin-1 signaling in ovarian cancer. |
19351767 |
Clin Cancer Res |
| Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. |
18474099 |
Breast Cancer Res |
| TAFII70 isoform-specific growth suppression correlates with its ability to complex with the GADD45a protein. |
15328371 |
Mol Cancer Res |
| The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. |
21501600 |
Biochem Pharmacol |
| The type III TGF-beta receptor suppresses breast cancer progression. |
17160136 |
J Clin Invest |
| Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues. |
23274563 |
Gynecol Oncol |
| Yeast screens identify the RNA polymerase II CTD and SPT5 as relevant targets of BRCA1 interaction. |
18197258 |
PLoS One |
